FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
https://www.cnbc.com/2024/04/30/ftc-challenges-patents-held-by-drugmakers-including-for-ozempic.html
Apr 30, 2024 - The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
0
Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents
https://seekingalpha.com/news/4096525-novo-teva-astrazeneca-issued-ftc-warnings-over-bogus-patents?source=feed_sector_healthcare
Apr 30, 2024 - The FTC has sent warning letters to 10 drugmakers, including Novo Nordisk (NVO), Teva (TEVA) and AstraZeneca (AZN) over improper patent listings. Read more here.
0
Pages: 1
Page 1